A BILL 
To amend subsection (q) of section 505 of the Federal Food, 
Drug, and Cosmetic Act to clarify the process for deny-
ing certain petitions whose primary purpose is to delay 
the approval of an application submitted under sub-
section (b)(2) or (j) of such section 505, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
03:43 May 01, 2019
H2387
2 
•HR 2387 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Stop The Overuse of 
2
Petitions and Get Affordable Medicines to Enter Soon Act 
3
of 2019’’ or the ‘‘STOP GAMES Act of 2019’’. 
4
SEC. 2. DENIAL OF PETITIONS WHOSE PRIMARY PURPOSE 
5
IS TO DELAY APPROVAL OF CERTAIN APPLI-
6
CATIONS. 
7
(a) IN GENERAL.—Subparagraph (E) of section 
8
505(q)(1) of the Federal Food, Drug, and Cosmetic Act 
9
(21 U.S.C. 355(q)(1)) is amended to read as follows: 
10
‘‘(E) DENIAL
BASED
ON
INTENT
TO 
11
DELAY.— 
12
‘‘(i) IN
GENERAL.—If the Secretary 
13
determines that a petition or a supplement 
14
to the petition was submitted with the pri-
15
mary purpose of delaying the approval of 
16
an application or the petition does not on 
17
its face raise valid scientific or regulatory 
18
issues, the Secretary may deny the petition 
19
at any point based on such determination. 
20
‘‘(ii) FACTORS.—The Secretary may 
21
issue guidance to describe the factors that 
22
will be used to determine under this sub-
23
paragraph whether a petition is submitted 
24
with the primary purpose of delaying the 
25
03:43 May 01, 2019
H2387
3 
•HR 2387 IH
approval of an application. Such factors 
1
shall include the following: 
2
‘‘(I) Submission of a petition 
3
where it appears, based on the date 
4
that relevant information relied upon 
5
in the petition became known to the 
6
petitioner (or reasonably should have 
7
been known to the petitioner), that 
8
the petitioner has taken an unreason-
9
able length of time to submit the peti-
10
tion. 
11
‘‘(II) Submission of multiple or 
12
serial petitions raising issues that rea-
13
sonably could have been known to the 
14
petitioner at the time of submission of 
15
the earlier petition or petitions. 
16
‘‘(III) Submission of a petition 
17
close in time to a known, first date 
18
upon which an application under sub-
19
section (b)(2) or (j) of this section or 
20
under section 351(k) of the Public 
21
Health Service Act could be approved 
22
(such as submission close in time to 
23
the expiration of a blocking patent or 
24
exclusivity). 
25
03:43 May 01, 2019
H2387
4 
•HR 2387 IH
‘‘(IV) Submission of a petition 
1
without any data or information in 
2
support of the scientific positions set 
3
forth in the petition. 
4
‘‘(V) Submission of a petition 
5
raising the same or substantially simi-
6
lar issues as a prior petition to which 
7
the Food and Drug Administration 
8
has already substantively responded, 
9
particularly where the subsequent sub-
10
mission closely follows in time the ear-
11
lier response. 
12
‘‘(VI) Submission of a petition 
13
concerning standards for approval of 
14
a drug product for which— 
15
‘‘(aa) the Food and Drug 
16
Administration has provided an 
17
opportunity 
for 
public 
input 
18
(such as when the Food and 
19
Drug Administration has issued 
20
draft or final product-specific 
21
guidance applicable to the drug 
22
product); and 
23
03:43 May 01, 2019
H2387
5 
•HR 2387 IH
‘‘(bb) the petitioner has not 
1
provided comment other than 
2
through the petition. 
3
‘‘(VII) Submission of a petition 
4
requesting that other applicants must 
5
meet standards for testing, data, or 
6
labeling for their products that are 
7
more onerous or rigorous than the 
8
standards applicable to the applicable 
9
listed drug or the petitioner’s version 
10
of the same product. 
11
‘‘(VIII) Other relevant consider-
12
ations, including the history of the pe-
13
titioner with the Food and Drug Ad-
14
ministration (such as whether the pe-
15
titioner has a history of submitting 
16
petitions which the Food and Drug 
17
Administration has determined were 
18
submitted with the primary purpose of 
19
delay). 
20
‘‘(iii) REFERRAL TO FTC.—If the Sec-
21
retary determines that a petition has been 
22
submitted with the primary purpose of de-
23
laying the approval of an application, as 
24
described in clause (i), the Secretary shall 
25
03:43 May 01, 2019
H2387
6 
•HR 2387 IH
refer the matter to the Federal Trade 
1
Commission.’’. 
2
(b) DEADLINE FOR SUBMISSION OF PETITIONS.— 
3
(1) 
DEADLINE.—Clause 
(i) 
of 
section 
4
505(q)(1)(A) of the Federal Food, Drug, and Cos-
5
metic Act (21 U.S.C. 355(q)(1)(A)) is amended to 
6
read as follows: 
7
‘‘(i) the request is in writing, is a pe-
8
tition submitted to the Secretary pursuant 
9
to section 10.30, 10.31, or 10.35 of title 
10
21, Code of Federal Regulations (or any 
11
successor regulations), and is submitted 
12
not later than 60 days after the informa-
13
tion upon which the petition is based first 
14
became known to the party on whose be-
15
half the petition is submitted; and’’. 
16
(2) CERTIFICATION.—Section 505(q)(1)(H) of 
17
the Federal Food, Drug, and Cosmetic Act (21 
18
U.S.C. 355(q)(1)) is amended by striking ‘‘I further 
19
certify that the information upon which I have based 
20
the action requested herein first became known to 
21
the party on whose behalf this petition is submitted 
22
on or about the following date: llll.’’ and in-
23
serting ‘‘I further certify that the information upon 
24
which I have based the action requested herein first 
25
03:43 May 01, 2019
H2387
7 
•HR 2387 IH
became known to the party on whose behalf this pe-
1
tition is submitted on or about llll, which 
2
date was not more than 60 days before the date of 
3
submitting this petition.’’. 
4
(c) REPORTING TO CONGRESS.—Section 505(q)(3) of 
5
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
6
355(q)(3)) is amended— 
7
(1) in the matter before subparagraph (A), by 
8
striking ‘‘specifies’’; 
9
(2) in subparagraphs (A), (B), (C), and (D), by 
10
striking ‘‘the number’’ and inserting ‘‘specifies the 
11
number’’; 
12
(3) in subparagraph (C), by striking ‘‘and’’ at 
13
the end; 
14
(4) in subparagraph (D), by striking the period 
15
at the end and inserting ‘‘; and’’; and 
16
(5) by adding at the end the following: 
17
‘‘(E)(i) lists each petition submitted during 
18
such period and, for each, identifies the peti-
19
tioner; 
20
‘‘(ii) quantifies the time and resources ex-
21
pended on each such petition; 
22
‘‘(iii) states the timing of the petition rel-
23
ative to the expiration date of the patents speci-
24
fied in the pending application in the certifi-
25
03:43 May 01, 2019
H2387
8 
•HR 2387 IH
cation 
under 
subsection 
(b)(2)(A) 
or 
1
(j)(2)(A)(vii), as applicable; 
2
‘‘(iv) quantifies the delay, if any, caused by 
3
any such petition on the approval of any appli-
4
cation submitted under subsection (b)(2) or (j), 
5
including a description of how any such delay is 
6
calculated and an estimate of when any delayed 
7
approval would have been granted absent the 
8
petition; and 
9
‘‘(v) in cases in which a pending applica-
10
tion and a petition with respect to such pending 
11
application are disposed of on the same or near-
12
ly the same date, states when the Food and 
13
Drug Administration would have disposed of 
14
the pending application absent the petition.’’. 
15
Æ 
03:43 May 01, 2019
H2387
